The competitive advantage of Amgen, like any other pharma company, lies in its patent. We invite readers to take a look at this issue – deeper.
Continue reading “Competitive Advantage of Amgen: November Update”Abbvie Dividend Stock Analysis: Patents Play
source: freepik
The biggest issue is of course the patent of Humira which will expire in 2023. If sales of that antirheumatic drug tumble, dividends will consequently follow and make AbbVie’s status as a dividend darling questionable. Here we try to dig deeper and give a detailed perspective about what really happens through our AbbVie dividend stock analysis.
Continue reading “Abbvie Dividend Stock Analysis: Patents Play”